Mate you calling out people pests that’s funny.
1. Is AGN its own drug class or unique? No
2. Has all peptides in the same drug class failed to get a response in humans? Yes
3. Has the company moved away in their presentations comparing itself to same peptides in the drug class? Yes
4. Are safety studies and preclinical studies cleared by previous peptides before they failed? Yes
The above answers tell you why I’m here. But apparently all you want to hear is the share price going to be pumping. Investigate the answers and if you have proof that this drug class works in humans post it and let’s have a discussion
AGN Media thread, page-209
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
72.0¢ |
Change
0.030(4.35%) |
Mkt cap ! $92.22M | |||
| Open | High | Low | Value | Volume |
| 70.0¢ | 72.5¢ | 70.0¢ | $43.97K | 62.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17447 | 72.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 72.5¢ | 4200 | 1 |
View Market Depth
| Last trade - 14.49pm 04/10/2024 (20 minute delay) ? |
| AGN (ASX) Chart |